吉非替尼治疗老年晚期非小细胞肺癌疗效观察

Efficacy and safety of gefitinib treated elded-patients with advanced non-small cell lungcancer

目的评价吉非替尼治疗非小细胞肺癌的疗效和毒副反应。方法 52例非小细胞肺癌,其中位年龄75岁,65岁以上者占34例,男性24例,女性28例,临床分期ⅢB期12例,Ⅳ期40例,腺癌32例,非腺癌20例,均未接受过一线治疗。治疗方案为吉非替尼250mg,1次/日,单药口服,每月1次胸腹部CT评价疗效。结果 52例患者中2例达CR,11例PR,20例SD,全组有效率25%,疾病控制率(CR+PR+SD)64.5%。腺癌组:有效率31.6%,疾病控制率73.7%,非腺癌组:有效率为7.1%,疾病控制率为21.4%,二者之间均有显著性差异(P<0.05)。常见的毒副作用为:皮疹和腹泻,Ⅰ和Ⅱ度不良反应皮疹(42.3%)和腹泻(26.9%)未见间质性肺病和常见的血液学毒性出现。结论吉非替尼对于老年晚期非小细胞肺癌有较好的有效性和安全性。

Objective To evaluate the efficacy and safety of Gifinitib as first-line treated elded-patients with advanceded non-small cell lung cancer.Methods 52 elded-patients with advened non-small cell lung cancer,Mid-aged was 75,34 were over 65 years,clinic stage were 12 ⅢB stage and 40 Ⅳ stage 32 of them were adenocarcinoma,other were no-adenocarcinma.no-one had first-line therapy.They were treated with gifitimib 250mg per day to evaluate the efficacy with CT of chest-abdom.Results 2 of 52 patients were CR,11 of them were PR,20 of them were SD,The oral response rate was 25%,disease control rate was 64.5%,The oral response rate and disease control rate of group of adenocarcinoma were 31.6% and 73.7%;The oral response rate and disease control rate of group of no-adenocarcinoma were 7.1% and 21.4%.There was statistically significant between these two groups（P0.05）.The common adverse effects were skin rash and diarrhea.Conclusion First-line treated elded-patient with gifinitib was efficive and safety